Literature DB >> 33676855

A practical approach to the evaluation and management of gastrointestinal symptoms in patients with systemic sclerosis.

Timothy Kaniecki1, Tsion Abdi2, Zsuzsanna H McMahan3.   

Abstract

The gastrointestinal (GI) tract is the most commonly affected internal organ system in systemic sclerosis (SSc). SSc may lead to impaired function in any region of the GI tract, from the esophagus to the anorectum, which causes significant morbidity as well as mortality in patient subsets. Given the low prevalence of SSc in the community, many rheumatologists may not have a systematic framework for diagnosing or treating the GI complaints in this disease. These practice recommendations aim to summarize and consolidate the current guidelines from the fields of gastroenterology and rheumatology and establish a symptom-based framework for diagnosis and management based on available evidence in the literature. Subject areas that are in need of additional research are also identified.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Gastrointestinal; Management; Scleroderma; Systemic sclerosis

Mesh:

Year:  2021        PMID: 33676855      PMCID: PMC8413400          DOI: 10.1016/j.berh.2021.101666

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.991


  100 in total

Review 1.  AGA technical review on nausea and vomiting.

Authors:  E M Quigley; W L Hasler; H P Parkman
Journal:  Gastroenterology       Date:  2001-01       Impact factor: 22.682

2.  Surgery for scleroderma of the esophagus: a 12-year experience.

Authors:  K A Mansour; C E Malone
Journal:  Ann Thorac Surg       Date:  1988-11       Impact factor: 4.330

3.  Clinical guideline: management of gastroparesis.

Authors:  Michael Camilleri; Henry P Parkman; Mehnaz A Shafi; Thomas L Abell; Lauren Gerson
Journal:  Am J Gastroenterol       Date:  2012-11-13       Impact factor: 10.864

Review 4.  Prucalopride for the treatment of constipation: a view from 2015 and beyond.

Authors:  Gabrio Bassotti; Paolo Usai Satta; Massimo Bellini
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2019-01-23       Impact factor: 3.869

5.  Early endoscopy in systemic sclerosis without gastrointestinal symptoms.

Authors:  Rene Thonhofer; Cornelia Siegel; Markus Trummer; Winfried Graninger
Journal:  Rheumatol Int       Date:  2010-08-14       Impact factor: 2.631

6.  High prevalence of eosinophilic esophagitis in patients with inherited connective tissue disorders.

Authors:  J Pablo Abonia; Ting Wen; Emily M Stucke; Tommie Grotjan; Molly S Griffith; Katherine A Kemme; Margaret H Collins; Philip E Putnam; James P Franciosi; Karl F von Tiehl; Brad T Tinkle; Keith A Marsolo; Lisa J Martin; Stephanie M Ware; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2013-04-19       Impact factor: 10.793

7.  Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation.

Authors:  John F Johanson; Dan Morton; Joseph Geenen; Ryuji Ueno
Journal:  Am J Gastroenterol       Date:  2007-10-04       Impact factor: 10.864

Review 8.  Evaluation of laboratory tests as a guide to diagnosis and therapy of myositis.

Authors:  T J Bohlmeyer; A H Wu; M B Perryman
Journal:  Rheum Dis Clin North Am       Date:  1994-11       Impact factor: 2.670

9.  Efficacy of anorectal biofeedback in scleroderma patients with fecal incontinence: a case-control study.

Authors:  Josephine Collins; Yoav Mazor; Michael Jones; John Kellow; Allison Malcolm
Journal:  Scand J Gastroenterol       Date:  2016-08-16       Impact factor: 2.423

10.  Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis?

Authors:  A Pakozdi; H Wilson; C M Black; C P Denton
Journal:  Clin Exp Rheumatol       Date:  2009 May-Jun       Impact factor: 4.473

View more
  3 in total

Review 1.  Gastrointestinal involvement in systemic sclerosis: pathogenesis, assessment and treatment.

Authors:  Elizabeth R Volkmann; Zsuzsanna McMahan
Journal:  Curr Opin Rheumatol       Date:  2022-08-19       Impact factor: 4.941

Review 2.  Management of scleroderma gastrointestinal disease: Lights and shadows.

Authors:  Jenice X Cheah; Dinesh Khanna; Zsuzsanna H McMahan
Journal:  J Scleroderma Relat Disord       Date:  2022-04-19

Review 3.  Rebuilding trust in proton pump inhibitor therapy.

Authors:  Alla Turshudzhyan; Sonia Samuel; Angela Tawfik; Micheal Tadros
Journal:  World J Gastroenterol       Date:  2022-06-28       Impact factor: 5.374

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.